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Despite significant advances in current understanding of mechanisms of pathogenesis
in Alzheimer’s disease (AD), attempts at drug development based on those discoveries
have failed to translate into effective, disease-modifying therapies. AD is a complex and
multifactorial disease comprising a range of aberrant cellular/molecular processes taking
part in different cell types and brain regions. As a consequence, therapeutics for AD
should be able to block or compensate multiple abnormal pathological events. Here, we
examine recent evidence that inhibition of protein tyrosine phosphatase 1B (PTP1B) may
represent a promising strategy to combat a variety of AD-related detrimental processes.
Besides its well described role as a negative regulator of insulin and leptin signaling,
PTB1B recently emerged as a modulator of various other processes in the central
nervous system (CNS) that are also implicated in AD. These include signaling pathways
germane to learning and memory, regulation of synapse dynamics, endoplasmic
reticulum (ER) stress and microglia-mediated neuroinflammation. We propose that
PTP1B inhibition may represent an attractive and yet unexplored therapeutic approach
to correct aberrant signaling pathways linked to AD.
Keywords: Alzheimer’s disease, protein tyrosine phosphatase 1B, diabetes, synaptic plasticity, neuroinflammation,
insulin signaling, leptin signaling, endoplasmic reticulum stress
INTRODUCTION
There are currently no disease-modifying therapies for Alzheimer’s disease (AD), and treatments
offer limited, temporary improvement in quality of life (Rafii and Aisen, 2015). This scenario
drives scientists and pharmaceutical companies into an intense search for effective therapies for
AD. Unfortunately, most if not all therapeutics that showed promise in preclinical models failed
to translate into effective therapies, as evidenced by numerous unsuccessful clinical trials. Because
AD comprises a broad range of deregulated processes taking place concomitantly, drugs acting on
multiple aberrant processes hold promise as candidates for AD therapeutics. Herein, we discuss
recent evidence indicating that protein tyrosine phosphatase 1B (PTP1B) inhibitors fulfill this
criterion.
A pivotal event in AD pathogenesis is the buildup in the brain of amyloid-β oligomers
(AβOs), neurotoxins that trigger synapse failure and lead to cognitive impairment
(Ferreira and Klein, 2011; Ferreira et al., 2015; Selkoe and Hardy, 2016). In neurons,
AβOs attack synapses (Lacor et al., 2004), altering membrane receptor composition
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(Lacor et al., 2007; De Felice et al., 2009; Jürgensen et al., 2011),
impairing synaptic plasticity (Lambert et al., 1998; Walsh et al.,
2002), and ultimately leading to synapse loss. Several signaling
pathways germane to learning andmemory are affected by AβOs.
Some of those are initiated by receptor tyrosine-kinases (RTKs)
such as the insulin receptor (IR; De Felice et al., 2009; Ma
et al., 2009), the leptin receptor (LepR; Marwarha et al., 2011;
Maioli et al., 2015) and the brain-derived neurotrophic factor
(BDNF) receptor, TrkB (Tong et al., 2004; Echeverria et al., 2007).
Additionally, AβOs activate microglia, triggering exacerbated
release of proinflammatory cytokines implicated in memory
impairment and mood alterations in mouse models of AD
(Ledo et al., 2013, 2016).
PTP1B emerged recently as a regulator of a variety of
processes within the central nervous system (CNS), many
of which therapeutically relevant for AD. Increased PTP1B
activity is associated with defective neuronal insulin and leptin
signaling (Zabolotny et al., 2002; Pandey et al., 2013, 2014),
pathways that are impaired in AD (Bomfim et al., 2012;
Bonda et al., 2014). Significantly, down-regulation of PTP1B
restores hypothalamic insulin and leptin signaling (Chiarreotto-
Ropelle et al., 2013; Lindtner et al., 2013; Pandey et al.,
2013, 2014; Yu et al., 2013). PTP1B down-regulates neuronal
BDNF-TrkB pathway, whereas PTP1B inhibition boosts BDNF
signaling (Ozek et al., 2014; Krishnan et al., 2015). Importantly,
mice lacking PTP1B in the hippocampus and cortex displayed
improved performance in the Barnes maze (Fuentes et al.,
2012), posing this phosphatase as a negative regulator of
spatial memory. PTP1B negatively regulates hippocampal store-
operated calcium entry (nSOC; Koss et al., 2013), an essential
process for the stabilization of mushroom spines that is impaired
in transgenic AD mice (Sun et al., 2014; Zhang H. et al., 2015).
Furthermore, PTP1B is up-regulated by endoplasmic reticulum
(ER) stress (Agouni et al., 2011; Popov, 2012; Hakim et al.,
2015), a neuronal response activated by AβOs and implicated
in synapse loss and cognitive decline in AD (Kam et al., 2013;
Lourenco et al., 2013). Finally, PTP1B is highly expressed in
hippocampal microglia (Pei et al., 1994), and was recently
described as a positive regulator of neuroinflammation (Song
et al., 2016).
In the following sections, we review evidence suggesting
that PTP1B modulates several CNS processes relevant to the
physiopathology of AD, making it an attractive target to be
explored in AD pharmacotherapy. Inhibiting PTP1B appears
as a promising, yet neglected strategy to combat multiple
aspects of AD.
INSULIN SIGNALING
Insulin signaling is initiated by activation of IR
autophosphorylation at tyrosine residues upon insulin binding
(Guo, 2014). The immediate effectors IRS-1 and IRS-2 (IR
substrate 1 and 2) are then recruited and activated by tyrosine
phosphorylation to propagate intracellular signaling (Guo,
2014). PTP1B dephosphorylates tyrosine residues in IR and
IRS-1 (Figure 1), reducing insulin sensitivity and shutting down
signaling (Goldstein et al., 2000; Bakke and Haj, 2015). PTP1B
deficient mice are hypersensitive to insulin and present low basal
glycemia and insulinemia (Elchebly et al., 1999), and inhibiting
PTP1B improves insulin signaling and reverses T2D phenotypes
(Malamas et al., 2000; Zinker et al., 2002; Gum et al., 2003;
Tamrakar et al., 2014). Conversely, exacerbated PTP1B activity
underlies insulin resistance in T2D (Zabolotny et al., 2002;
González-Rodríguez et al., 2010).
An epidemiological correlation between AD and T2D exists,
with each disease increasing the risk of developing the other
(Ott et al., 1996; Craft and Watson, 2004; De Felice, 2013a,b).
However, the mechanisms underlying this connection remain
elusive. A breakthrough discovery that contributed to current
understanding of such mechanisms was that neurons exposed to
AβOs become insensitive to insulin (Zhao et al., 2008; De Felice
et al., 2009). Further studies showed that AβOs impair insulin
signaling by increasing IRS-1 inhibitory serine phosphorylation
and decreasing activating tyrosine phosphorylation (Bomfim
et al., 2012). Importantly, defective insulin signaling was
confirmed in post mortem AD brains (Bomfim et al., 2012;
Talbot et al., 2012). Conversely, boosting insulin signaling
protects synapses against AβOs toxicity (De Felice et al., 2009).
These discoveries paved the way for a whole new aspect of
AD, which has provided important advances of therapeutic
relevance. For instance, anti-diabetic drugs developed to treat
insulin resistance in T2D have shown promising preclinical
results, protecting synapses, preventing inhibition of IRS-1
and, most importantly, ameliorating cognitive phenotypes in
animal models of AD (McClean et al., 2011; Bomfim et al.,
2012; Hansen et al., 2015; Qi et al., 2016). Those studies have
provided molecular grounds for on-going clinical trials aimed
at testing the efficacy of intranasal insulin and glucagon-like
peptide 1 (GLP-1) analogs in AD (De Felice and Ferreira,
2014).
Thus, it seems reasonable to predict that PTP1B
inhibitors—which restore insulin sensitivity in T2D models
(Malamas et al., 2000; Zinker et al., 2002; Gum et al., 2003;
Panzhinskiy et al., 2013; Tamrakar et al., 2014)—may rescue
neurons from defective insulin signaling in AD. Although this
hypothesis has not yet been tested directly, there is evidence
from non-AD models of neuronal insulin resistance validating
PTP1B inhibition as an effective approach to rescue neuronal
insulin signaling (Krishnan et al., 2015; Qin et al., 2015a; Zhang
Z. Y. et al., 2015).
LEPTIN SIGNALING
In obesity, defective hypothalamic leptin signaling impairs
sensing and processing of satiety signals, leading to increased
caloric intake and decreased energy expenditure (Halaas et al.,
1995; Farooqi et al., 1999; Morton et al., 2006). Ob/Ob
mice, which do not produce leptin, exhibit increased food
intake and become profoundly obese (Zhang et al., 1994).
Leptin signaling is initiated by binding of leptin to LepR,
leading to tyrosine autophosphorylation of LepR and subsequent
phosphorylation of Janus kinase 2 (JAK2), which propagates
downstream intracellular signaling (Iida et al., 1996; Fei et al.,
1997).
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FIGURE 1 | Protein tyrosine phosphatase 1B (PTP1B) regulates multiple mechanisms implicated in the pathogenesis of Alzheimer’s disease (AD).
In microglia, PTP1B is a positive regulator of neuroinflammation. PTP1B activates Src via dephosphorylation at a negative regulatory site. Src, in turn, indirectly
activates NF-κB, a transcriptional regulator of proinflammatory mediators including TNF-α, IL-1β, COX-2 and inducible nitric oxide synthase (iNOS). In neurons,
PTP1B is upregulated by endoplasmic reticulum (ER) stress, a cellular response activated by amyloid-β oligomers (AβOs) in AD. Elevated PTP1B inhibits signaling by
receptor tyrosine kinases germane to synaptic plasticity, cognition and memory. Substrates for PTP1B in neurons that have been implicated in AD include the insulin
receptor (InsR) and its substrate IRS-1, the leptin receptor (LepR) and its immediate downstream effector Janus kinase 2 (JAK2), and the brain-derived neurotrophic
factor (BDNF) receptor (TrkB). PTP1B further regulates neuronal store-operated calcium entry (nSOC), a mechanism required for spine/synaptic stability found to be
impaired in models of AD.
Strong evidence implicates PTP1B in obesity-associated
hypothalamic leptin resistance (Cheng et al., 2002; Zabolotny
et al., 2002). PTP1B dephosphorylates LepR and JAK2,
functioning as a negative regulator of leptin signaling (Figure 1).
PTP1B-null mice are resistant to weight gain induced by high-fat
diet (HFD) or by deletion of the leptin gene, suggesting PTP1B
inhibition as a strategy to rescue leptin signaling in food intake
disorders and obesity (Elchebly et al., 1999; Cheng et al.,
2002).
Beyond hypothalamic signaling, leptin plays important roles
in the CNS. LepRs are highly expressed in the hippocampus
(Huang et al., 1996; Mercer et al., 1996; Scott et al., 2009) where
leptin signaling is important for cognition and memory (Irving
and Harvey, 2014). Aβ down-regulates hippocampal leptin and
LepR expression (Marwarha et al., 2010; Bonda et al., 2014).
Interestingly, leptin prevents hippocampal synaptic disruption
and neuronal death induced by Aβ (Doherty et al., 2013). Leptin
also modifies Aβ levels (Fewlass et al., 2004) and reduces tau
phosphorylation in neuronal cells (Greco et al., 2008, 2009a,b).
Importantly, neuronal leptin resistance has been described in
the AD hippocampus (Bonda et al., 2014; Maioli et al., 2015),
further underlining the relevance of defective leptin signaling
in AD.
Leptin signaling has been proposed as a neuroprotective target
in AD (Gomes et al., 2014; Johnston et al., 2014). Because direct
administration of leptin or LepR agonists in conditions of leptin
resistance may not result in the desired biological effect, a more
attractive approach to boost leptin signaling in AD would be to
reverse neuronal leptin resistance. The evidence described above
suggests that recovery of leptin sensitivity could be achieved by
PTP1B inhibitors.
ENDOPLASMIC RETICULUM STRESS
ER stress and activation of the unfolded protein response (UPR)
are important toxic mechanisms in AD (Lourenco et al., 2015).
We recently demonstrated that AβOs trigger ER stress in
hippocampal neurons in a mechanism that requires TNF-
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α receptor activation (Lourenco et al., 2013). ER stress
triggered by TNF-α has also been linked to peripheral insulin
resistance in obesity and diabetes (reviewed in Hotamisligil,
2010).
PTP1B localizes predominantly to the cytoplasmic surface
of the ER (Haj et al., 2002) and mediates ER stress signaling
(Wang et al., 2009). Downregulation of PTP1B ameliorates
ER stress in obesity and diabetes models (Delibegovic et al.,
2009; Agouni et al., 2011; Owen et al., 2013). Two of the
UPR branches activated upon ER stress involve inositol-
requiring enzyme 1 (IRE-1) and activating transcription factor
6 (ATF6). Interestingly, PTP1B potentiates IRE-1-mediated ER
stress response and its expression is regulated by ATF6 (Gu
et al., 2004; Wang et al., 2009). Moreover, recent evidence
links hypothalamic ER stress and activation of the UPR to
development of PTP1B-mediated leptin resistance and increased
food intake following chronic sleep fragmentation in mice
(Hakim et al., 2015).
Collectively, data suggest that PTP1B mediates the toxic
consequences of neuronal ER stress (Figure 1). It has been
hypothesized that PTP1B may be a key link between insulin
signaling and ER stress (Popov, 2012). This raises the possibility
that PTP1B inhibitors may be able to compensate the detrimental
impact of ER stress on synapse stability and cognition in AD.
SYNAPTIC PLASTICITY, STABILITY AND
MEMORY
The functions of PTP1B in neurophysiology are gaining traction
as novel roles for PTP1B in the brain are discovered. PTP1B
has been implicated in a variety of neuronal processes, including
some related to synapse biology that are potentially relevant to
the pathogenesis of AD.
BDNF is a major regulator of synaptic plasticity. BDNF
signaling through its receptor, TrkB,modulates synapse structure
and function to produce long-term potentiation (LTP), a form
of activity-dependent synaptic plasticity thought to underlie
learning and memory (Leal et al., 2015). AD brains display
reduced BDNF levels in clinical (Phillips et al., 1991; Connor
et al., 1997; Soontornniyomkij et al., 1999) and preclinical disease
stages (Peng et al., 2005). Conversely, BDNF is neuroprotective
in animal models of AD (Arancibia et al., 2008; Nagahara et al.,
2009). Therefore, stimulating BDNF signaling represents an
attractive approach in AD therapy.
Recent studies showed that PTP1B downregulates BDNF
signaling through dephosphorylation of TrkB (Ozek et al.,
2014; Krishnan et al., 2015; Figure 1). Ptpn1−/− mice are
hypersensitive to BDNF, and pharmacological inhibition of
PTP1B increases neuronal responsiveness BDNF (Ozek et al.,
2014). PTP1B inhibition may, thus, represent a means to
enhance BDNF signaling, improving synaptic plasticity and
cognition in AD.
PTP1B has further been implicated in hippocampal synapse
formation and learning (Fuentes et al., 2012). PTP1B is present
in dendritic spines of hippocampal neurons, and functional
or genetic PTP1B deficiency affects spine morphology and
leads to disorganization of pre- and post-synaptic terminals.
Interestingly, mice lacking PTP1B in the hippocampus and
cortex exhibit improved performance in the Barnes maze
compared to wild-type controls, posing this phosphatase as a
negative regulator of spatial memory (Fuentes et al., 2012).
Neuronal store-operated calcium entry (nSOC) is essential
for stabilization of mushroom spines in hippocampal neurons
(Sun et al., 2014). AD mice exhibit impaired nSOC, which causes
destabilization and loss of spines through a mechanism involving
overactivation of metabotropic glutamate receptor 5 (mGluR5;
Sun et al., 2014; Zhang H. et al., 2015). PTP1B is a negative
regulator of hippocampal nSOC (Koss et al., 2013; Figure 1),
suggesting PTP1B inhibition may restore deficient nSOC.
Collectively, these findings suggest PTP1B inhibition may
result in improved synapse plasticity, function and stability,
ultimately enhancing cognitive performance.
MICROGLIA-MEDIATED
NEUROINFLAMMATION
Chronic neuroinflammation is an important feature of AD
(Heneka et al., 2015; Heppner et al., 2015). Evidence for activated
microglia has been described in transgenic AD mice (Frautschy
et al., 1998; Bornemann et al., 2001) and in AD brains (Cagnin
et al., 2001; Edison et al., 2008). Microglia are implicated in
cognitive impairment in AD through sustained secretion of
neurotoxic cytokines (Wang et al., 2015) and synapse pruning
(Hong et al., 2016; Lui et al., 2016). Injection of AβOs in mouse
brains inducesmicroglia-mediated neuroinflammation (Xu et al.,
2016), leading to memory impairment and mood alterations
(Ledo et al., 2013, 2016). Direct activation of microglia by AβOs
was recently demonstrated in primary microglial cultures (Ledo
et al., 2016).
Activated microglia are the main source of proinflammatory
cytokines such as TNF-α and IL-1β in the brain (Wang
et al., 2015). TNF-α is implicated in memory impairment
caused by AβOs (Bomfim et al., 2012; Lourenco et al., 2013).
Activation of TNF-α signaling is associated with inhibition of
IRS-1 in hippocampal neurons (Bomfim et al., 2012). TNF-α
is also implicated in peripheral insulin resistance in diabetes
(Hotamisligil et al., 1993; Hotamisligil and Spiegelman, 1994),
and it has been proposed that neuronal insulin resistance
induced by TNF-α may underlie the connection between
diabetes and AD (De Felice and Ferreira, 2014). IL-1β has been
described as a mediator of cognitive impairment associated with
peripheral and central inflammation by disrupting hippocampal
synaptic plasticity (Di Filippo et al., 2013; Erion et al., 2014).
These lines of evidence support dampening microglia-mediated
neuroinflammation as an attractive therapeutic approach in
AD (Ransohoff, 2016; Santos et al., 2016; Wes et al.,
2016).
PTP1B is regulated by proinflammatory signals and is
highly expressed in hippocampal microglia in AD (Pei et al.,
1994). Interestingly, a recent study unraveled a novel role for
PTP1B as a positive regulator of neuroinflammation (Song
et al., 2016). PTP1B levels are increased in LPS injected
brain, and PTP1B overexpression potentiates microglial
responses via dephosphorylation/activation of Src and nuclear
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translocation of NF-κB, leading to increased expression
of proinflammatory molecules including TNF-α, IL-1β,
cyclooxigenase-2 and inducible nitric oxide synthase (iNOS;
Figure 1). Significantly, LPS-induced neuroinflammation
is attenuated by pharmacological PTP1B inhibitors (Song
et al., 2016). Conversely, TNF-α increases PTP1B expression
via NFκB in adipose tissue of HFD mice (Zabolotny et al.,
2008) and in organotypic hypothalamic cultures (Ito et al.,
2012), further exacerbating inflammation in a feed-forward
mechanism. This suggests that pharmacological inhibition of
PTP1B may constitute a therapeutic strategy to counteract
neuroinflammation.
PTP1B INHIBITORS AS DRUG
CANDIDATES FOR NEUROLOGICAL
DISEASES
PTP1B has long been pursued as a therapeutic target in human
diseases, particularly in diabetes and obesity (Zhang and Lee,
2003). Multiple PTP1B inhibitors have been developed and
tested in preclinical models, validating the concept of PTP1B
inhibition as an effective therapeutic approach for diabetes
(Tamrakar et al., 2014). Nevertheless, certain structural features
of PTP1B complicate the development of small molecule
inhibitors with fundamental characteristics required for drug
candidates, namely, specificity/selectivity and bioavailabilty.
First, the active sites of protein tyrosine phosphatases (PTPs)
are highly conserved among the more than 100 family members
(Tonks, 2013). Therefore, inhibitors designed to bind to the
active site of PTP1B often inhibit other PTPs as well, leading
to off-target effects (Tamrakar et al., 2014; Tautz, 2015). Second,
most inhibitors developed so far are phosphotyrosine-mimicking
molecules bearing a charged group, which drastically affects
pharmacokinetics (Tautz, 2015). For those reasons, few PTP1B
inhibitors have reached clinical trials, and none have made it
through phase II tests (Tamrakar et al., 2014; Tautz, 2015).
In AD, the blood-brain barrier (BBB) represents an
additional obstacle drugs need to overcome to reach the
CNS. Fortunately, however, significant advances have been
achieved in developing effective PTP1B inhibitors with potential
for clinical use. For example, an important recent study
provided compelling evidence that potent and selective PTP1B
inhibitors administered peripherally (e.g., intraperitoneally or
subcutaneously) inhibit PTP1B activity in the brain (Krishnan
et al., 2015). MeCP2 deficient mice, a model of Rett syndrome,
exhibit increased PTP1B expression, leading to defective brain
insulin signaling and impaired glucose metabolism. This was
associated with neurological phenotypes in female mice and
reduced lifespan in male mice, recapitulating Rett syndrome in
humans. Remarkably, long-term systemic treatment with two
distinct PTP1B inhibitors, CPT157633 and UA0713, rescued
disease phenotypes in MeCP2 deficient mice. Moreover, PTP1B
inhibitors increased tyrosine phosphorylation of TrkB, leading
to enhanced signaling in response to BDNF in the forebrains of
MeCP2 deficient mice (Krishnan et al., 2015).
Another recent study showed that intraperitoneal
administration of trodusquemine, a selective BBB-permeant
(Ahima et al., 2002; Lantz et al., 2010) PTP1B inhibitor,
relieved anxiety in LMO4 knockout mice exhibiting impaired
endocannabinoid signaling due to increased PTP1B activity in
amygdala (Qin et al., 2015b). Those studies support the feasibility
of using peripherally administered PTP1B inhibitors to treat
CNS disorders.
CONCLUSION
Compelling recent findings suggest PTP1B holds potential
as a therapeutic target in AD. Results indicate that PTP1B
regulates distinct CNS responses depending on cell type: while
PTP1B modulates insulin and leptin signaling in neurons,
it regulates astrocyte differentiation (Yamada et al., 2013)
and proinflammatory responses in microglia. Because PTP1B
participates in several cellular/molecular processes linked to AD
pathogenesis (Figure 1), compounds capable of reaching the
CNS and inhibiting PTP1B activity in neurons and/or glial cells
may rescue multiple aberrant processes associated with cognitive
decline and neurodegeneration in AD.
Detailed preclinical studies are warranted to validate the
potential benefits of PTP1B inhibition in AD models. Because
PTP1B may interfere with pathological mechanisms that operate
at different disease stages, it will be important to investigate
whether PTP1B inhibition delays, prevents or slows down disease
progression or temporarily ameliorates symptoms.
Finally, the above described pathological mechanisms in
which PTP1B has been implicated are not exclusively associated
with AD, but also with other neurological disorders. This raises
the possibility that PTP1B inhibition may be useful for treatment
of other brain disorders related to metabolic deregulation, and
perhaps even in normal, age-related cognitive decline.
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